Integral Molecular, Inc.

Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, and transporters. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Its customers include all of the top pharmaceutical and biotechnology companies.

Founded in 2001, the Company holds intellectual property rights covering all aspects of its technologies, including core patents licensed exclusively from the University of Pennsylvania.